In EDS ansehen

Soluble terminal complement complex blood levels are elevated in schizophrenia

Gespeichert in:
Bibliographische Detailangaben
Titel: Soluble terminal complement complex blood levels are elevated in schizophrenia
Autoren: Susa Savukoski, Marco Mannes, Lisa Wohlgemuth, Anke Schultze, Paul C. Guest, Gabriela Meyer-Lotz, Henrik Dobrowolny, Borna Relja, Markus Huber-Lang, Johann Steiner
Quelle: Eur Arch Psychiatry Clin Neurosci
Verlagsinformationen: Springer Science and Business Media LLC, 2024.
Publikationsjahr: 2024
Schlagwörter: Male, Adult, 0301 basic medicine, Original Paper, 0303 health sciences, Female [MeSH], Complement C4/metabolism [MeSH], Confounders, C5a, Adult [MeSH], C4, Humans [MeSH], Middle Aged [MeSH], C-Reactive Protein/metabolism [MeSH], Classical pathway, Schizophrenia/blood [MeSH], Complement C5a [MeSH], Complement system, First-episode psychosis, Male [MeSH], Young Adult [MeSH], Complement C4/analysis [MeSH], C-Reactive Protein/analysis [MeSH], sTCC, Complement Membrane Attack Complex/metabolism [MeSH], Complement C4, Complement C5a, Complement Membrane Attack Complex, Middle Aged, Young Adult, 03 medical and health sciences, C-Reactive Protein, Schizophrenia, Humans, Female
Beschreibung: The role of the complement system in schizophrenia (Sz) is inconclusive due to heterogeneity of the disease and study designs. Here, we assessed the levels of complement activation products and functionality of the classical pathway in acutely ill unmedicated Sz patients at baseline and after 6 weeks of treatment versus matched controls. The study included analyses of the terminal complement complex (sTCC) and C5a in plasma from 96 patients and 96 controls by enzyme-linked immunosorbent assay. Sub-group analysis of serum was conducted for measurement of C4 component and activity of the classical pathway (28 and 24 cases per cohort, respectively). We found no differences in levels of C5a, C4 and classical pathway function in patients versus controls. Plasma sTCC was significantly higher in patients [486 (392–659) ng/mL, n = 96] compared to controls [389 (304–612) ng/mL, n = 96] (p = 0.027, δ = 0.185), but not associated with clinical symptom ratings or treatment. The differences in sTCC between Sz and controls were confirmed using an Aligned Rank Transformation model considering the covariates age and sex (p = 0.040). Additional analysis showed that sTCC was significantly associated with C-reactive protein (CRP; p = 0.006). These findings suggest that sTCC plays a role in Sz as a trait marker of non-specific chronic immune activation, as previously described for CRP. Future longitudinal analyses with more sampling time points from early recognition centres for psychoses may be helpful to better understand the temporal dynamics of innate immune system changes during psychosis development.
Publikationsart: Article
Other literature type
Sprache: English
ISSN: 1433-8491
0940-1334
DOI: 10.1007/s00406-023-01738-z
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38243017
https://repository.publisso.de/resource/frl:6521635
Rights: CC BY
Dokumentencode: edsair.doi.dedup.....e4d7768cbd4f8c930a00eb9ea03c3591
Datenbank: OpenAIRE
Beschreibung
Abstract:The role of the complement system in schizophrenia (Sz) is inconclusive due to heterogeneity of the disease and study designs. Here, we assessed the levels of complement activation products and functionality of the classical pathway in acutely ill unmedicated Sz patients at baseline and after 6 weeks of treatment versus matched controls. The study included analyses of the terminal complement complex (sTCC) and C5a in plasma from 96 patients and 96 controls by enzyme-linked immunosorbent assay. Sub-group analysis of serum was conducted for measurement of C4 component and activity of the classical pathway (28 and 24 cases per cohort, respectively). We found no differences in levels of C5a, C4 and classical pathway function in patients versus controls. Plasma sTCC was significantly higher in patients [486 (392–659) ng/mL, n = 96] compared to controls [389 (304–612) ng/mL, n = 96] (p = 0.027, δ = 0.185), but not associated with clinical symptom ratings or treatment. The differences in sTCC between Sz and controls were confirmed using an Aligned Rank Transformation model considering the covariates age and sex (p = 0.040). Additional analysis showed that sTCC was significantly associated with C-reactive protein (CRP; p = 0.006). These findings suggest that sTCC plays a role in Sz as a trait marker of non-specific chronic immune activation, as previously described for CRP. Future longitudinal analyses with more sampling time points from early recognition centres for psychoses may be helpful to better understand the temporal dynamics of innate immune system changes during psychosis development.
ISSN:14338491
09401334
DOI:10.1007/s00406-023-01738-z